- Home
- ICU vs CODX Comparison
ICU vs CODX Comparison
Compare ICU & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- CODX
- Stock Information
- Founded
- ICU 2018
- CODX 2013
- Country
- ICU United States
- CODX United States
- Employees
- ICU N/A
- CODX N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- CODX Medical/Dental Instruments
- Sector
- ICU Health Care
- CODX Health Care
- Exchange
- ICU Nasdaq
- CODX Nasdaq
- Market Cap
- ICU 10.4M
- CODX 9.8M
- IPO Year
- ICU N/A
- CODX 2017
- Fundamental
- Price
- ICU $0.61
- CODX $0.25
- Analyst Decision
- ICU
- CODX Buy
- Analyst Count
- ICU 0
- CODX 2
- Target Price
- ICU N/A
- CODX $5.50
- AVG Volume (30 Days)
- ICU 19.2M
- CODX 972.9K
- Earning Date
- ICU 08-12-2025
- CODX 08-07-2025
- Dividend Yield
- ICU N/A
- CODX N/A
- EPS Growth
- ICU N/A
- CODX N/A
- EPS
- ICU N/A
- CODX N/A
- Revenue
- ICU $428,000.00
- CODX $3,497,583.00
- Revenue This Year
- ICU $754.07
- CODX N/A
- Revenue Next Year
- ICU $100.09
- CODX $42.11
- P/E Ratio
- ICU N/A
- CODX N/A
- Revenue Growth
- ICU N/A
- CODX N/A
- 52 Week Low
- ICU $0.31
- CODX $0.23
- 52 Week High
- ICU $9.56
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- ICU 41.48
- CODX 40.44
- Support Level
- ICU $0.52
- CODX $0.24
- Resistance Level
- ICU $0.83
- CODX $0.29
- Average True Range (ATR)
- ICU 0.16
- CODX 0.02
- MACD
- ICU 0.04
- CODX -0.00
- Stochastic Oscillator
- ICU 50.89
- CODX 13.79
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.